{"filing":{"accession_number":"0001356576-26-000025","cik":"0001356576","ticker":"SUPN","company_name":"SUPERNUS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"supn-20260517.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000025/supn-20260517.htm"},"events":[{"id":9854,"run_id":8637,"accession_number":"0001356576-26-000025","anchor_item_number":"2.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The Company disclosed achievement of Milestone 1 under a Contingent Value Right Agreement, triggering a direct financial obligation to pay approximately $33.4 million ($0.50 per CVR) in cash within 20 business days. While this is a material cash obligation disclosed under Item 2.03, it does not fit cleanly into the more specific event categories (it is neither a covenant breach, debt issuance, nor a traditional financial obligation like a loan). The CVR payment obligation is a contingent consideration from a prior transaction, making \"other_material\" the most appropriate classification.","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":666,"accession_number":"0001356576-26-000025","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company disclosed achievement of Milestone 1 under a Contingent Value Right Agreement, triggering a direct financial obligation to pay approximately $33.4 million ($0.50 per CVR) in cash within 20 business days. While this is a material cash obligation disclosed under Item 2.03, it does not fit cleanly into the more specific event categories (it is neither a covenant breach, debt issuance, nor a traditional financial obligation like a loan). The CVR payment obligation is a contingent consideration from a prior transaction, making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:51:05.839388+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":666,"accession_number":"0001356576-26-000025","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company disclosed achievement of Milestone 1 under a Contingent Value Right Agreement, triggering a direct financial obligation to pay approximately $33.4 million ($0.50 per CVR) in cash within 20 business days. While this is a material cash obligation disclosed under Item 2.03, it does not fit cleanly into the more specific event categories (it is neither a covenant breach, debt issuance, nor a traditional financial obligation like a loan). The CVR payment obligation is a contingent consideration from a prior transaction, making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:51:05.839388+00:00","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-05-20"}]}